braf
No description yet: the sentence for this tag has not been written. 5 records carry it: 3 biomarkers, 2 people.
By kind
5 records
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
BRAF class II and class III mutations (non-V600) BRAF Class II and III BRAF mutations sit outside codon 600 and signal as pairs (class II) or by leaning on RAS (class III). Approved BRAF inhibitors do not work on them, and no drug is yet approved for them; pan-RAF inhibitors are in trials. | Melanoma, Non-small-cell lung cancer, Colorectal cancer | none | biomarker, no-approval | ||
BRAF fusion or rearrangement BRAF A BRAF fusion joins another gene to the BRAF kinase, most often KIAA1549 in paediatric low-grade glioma. Tovorafenib is approved for children whose relapsed low-grade glioma carries a BRAF fusion or V600 mutation. | Paediatric low-grade glioma, Melanoma | none | biomarker | ||
BRAF V600E (and V600K) BRAF V600E is the BRAF change that drives half of melanomas and many thyroid, bowel, lung and brain tumours. BRAF plus MEK inhibitors are approved for it in melanoma, lung, thyroid and, tumour-agnostically, any solid tumour; in bowel cancer it is treated with encorafenib and cetuximab. | Melanoma, Advanced melanoma, Colorectal cancer | none | biomarker | ||
Maria E. Cabanillas Professor of Endocrine Neoplasia and Hormonal Disorders, MD Anderson Cancer Center · MD Anderson Cancer Center Turned anaplastic thyroid cancer from a death sentence into a treatable disease with BRAF-targeted therapy and neoadjuvant strategies. | Thyroid cancer | none | thyroid, neoadjuvant | ||
Scott Kopetz Professor of Gastrointestinal Medical Oncology, MD Anderson Cancer Center · MD Anderson Cancer Center Led BEACON and BREAKWATER, the trials that gave BRAF-mutant colorectal cancer its first targeted therapies. | Colorectal cancer | none | colorectal, targeted-therapy |